Department of Pharmaceutical Care Services, Bassett Healthcare, One Atwell Road, Cooperstown, NY 13326, USA.
Curr Infect Dis Rep. 2007 Jan;9(1):29-34. doi: 10.1007/s11908-007-0019-y.
Pediatric and adult community-acquired respiratory tract infections remain some of the most common reasons for visits to primary care practitioners, and the antibiotics used to treat them are historically highly profitable for their manufacturers. Despite these facts and the continued evolving need for new treatments for these infections, virtually no new agents have been developed in the past decade. This review explores some regulatory guidelines that could potentially explain the dearth of development, and it provides some practical answers for resolving them.
儿科和成人社区获得性呼吸道感染仍然是大多数人去初级保健医生处就诊的最常见原因之一,用于治疗这些感染的抗生素在历史上对其制造商来说是非常有利可图的。尽管存在这些事实以及对这些感染的新治疗方法的持续不断的需求,但在过去十年中实际上没有开发出任何新的药物。本文探讨了一些可能解释这一发展不足的监管指南,并为解决这些问题提供了一些实际的答案。